The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors

Neuropharmacology
Lucinda J StewardJudith A Pratt

Abstract

The ability of antipsychotic drugs to affect 5-HT(2A) receptor function has been widely suggested to contribute to their therapeutic properties. We have compared the ability of the antipsychotic drugs clozapine and haloperidol, alone and in combination with chronic phencyclidine (PCP), to modulate 5-HT(2A) receptor binding and mRNA. Acute (i.p. 45 min) and chronic (21-day) clozapine (osmotic minipump (OMP); 20 mg/kg/day) produced widespread decreases in 5-HT(2A) receptor binding (-60%-80%), measured using [(3)H]ketanserin autoradiography. Conversely, 5-HT(2A) mRNA levels, determined using in-situ hybridisation, were modestly increased by chronic clozapine treatment (+10%-30%). Chronic PCP treatment, at a dose (2.58 mg/kg i.p. intermittently for 28 days) that reproduces many of the neurochemical deficits of schizophrenia, decreased 5-HT(2A) receptor binding in the prefrontal cortex (PFC; -16%), consistent with the changes in post-mortem brain tissue from schizophrenic patients. Combined chronic PCP (i.p.) and clozapine (OMP) treatment down-regulated 5-HT(2A) receptor binding in many areas, similar to the effects of clozapine treatment alone and clozapine further enhanced the effects of PCP in the prefrontal cortex. In contrast 5...Continue Reading

References

Dec 1, 1992·Archives of General Psychiatry·A WolkinJ Rotrosen
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Dec 1, 1989·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R S Mansbach, M A Geyer
Feb 12, 1985·European Journal of Pharmacology·T NabeshimaT Kameyama
May 6, 1983·European Journal of Pharmacology·G P ReynoldsC D Marsden
Oct 14, 1994·European Journal of Pharmacology·M KuoppamäkiJ Hietala
Apr 1, 1994·Brain Research. Molecular Brain Research·M PompeianoG Mengod
Oct 1, 1993·Archives of General Psychiatry·M LaruelleJ E Kleinman
Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R J BaldessariniB M Cohen
Nov 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P W BurnetP J Harrison
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Apr 11, 1997·Schizophrenia Research·C L Beasley, G P Reynolds
Aug 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D JentschR H Roth
Jan 24, 1998·Naunyn-Schmiedeberg's Archives of Pharmacology·J F López-GiménezM T Vilaró
Aug 1, 1997·Brain Research. Molecular Brain Research·P R BucklandP McGuffin
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·R L Jakab, P S Goldman-Rakic
Jan 28, 1998·Critical Reviews in Neurobiology·C A Tamminga
Jun 3, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R Y Wang, X Liang
Jun 20, 1998·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·C WuS K Singh
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, R H Roth
Jun 24, 1999·The Journal of Comparative Neurology·V Cornea-HébertL Descarries
Jul 23, 1999·Annals of the New York Academy of Sciences·N R SwerdlowM A Geyer
Feb 9, 2000·Psychopharmacology·G Remington, S Kapur
May 5, 2000·The Cochrane Database of Systematic Reviews·R LewisM Leitner
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Susan M CochranBrian J Morris
Mar 1, 1959·A.M.A. Archives of Neurology and Psychiatry·E D LUBYR KELLEY

❮ Previous
Next ❯

Citations

Jan 8, 2008·The Journal of Pharmacology and Experimental Therapeutics·Mohamed Rafiuddin AhmedEugenia V Gurevich
Feb 5, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neil DawsonJudith A Pratt
Sep 3, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jiamei LianChao Deng
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
Jan 2, 2010·Behavioural Brain Research·Trisha A JenkinsStephen J Cooper
Jun 16, 2009·Neuropharmacology·M Margarita Behrens, Terrence J Sejnowski
Jul 17, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Jianliang NiChen Zhang
Jul 28, 2005·Pharmacology, Biochemistry, and Behavior·Renee L Hayslett, Yousef Tizabi
Oct 9, 2013·The International Journal of Neuropsychopharmacology·Herbert Y MeltzerMasakuni Horiguchi
Jan 5, 2012·Psychiatry Investigation·Nishant GoyalHaque Nizamie
Apr 30, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Abdullah BoluTaner Oznur
Nov 19, 2019·Clinical Neuropharmacology·Özcan UzunBegüm Oğur
Aug 16, 2017·Molecular Psychiatry·A B NiculescuD R Salomon
Jul 31, 2021·World Journal of Psychiatry·Mary V Seeman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.